vs
Side-by-side financial comparison of Atlas Energy Solutions Inc. (AESI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $265.6M, roughly 1.2× Atlas Energy Solutions Inc.). Bio-Techne runs the higher net margin — 16.4% vs 0.5%, a 15.9% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -10.8%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -3.9%).
Atlas Copco Group is a Swedish multinational industrial company. It manufactures compressors, vacuum equipment, pumps, generators, assembly tools, quality assurance equipment and other products and systems for industrial applications and mobile power generation. The products are sold in around 180 countries.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
AESI vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $265.6M | $311.4M |
| Net Profit | $1.2M | $51.0M |
| Gross Margin | 2.4% | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | 0.5% | 16.4% |
| Revenue YoY | -10.8% | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | $0.01 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $265.6M | $311.4M | ||
| Q4 25 | $249.4M | $295.9M | ||
| Q3 25 | $259.6M | — | ||
| Q2 25 | $288.7M | $317.0M | ||
| Q1 25 | $297.6M | $316.2M | ||
| Q4 24 | $271.3M | $297.0M | ||
| Q3 24 | $304.4M | $289.5M | ||
| Q2 24 | $287.5M | $306.1M |
| Q1 26 | $1.2M | $51.0M | ||
| Q4 25 | $-22.2M | $38.0M | ||
| Q3 25 | $-23.7M | — | ||
| Q2 25 | $-5.6M | $-17.7M | ||
| Q1 25 | $1.2M | $22.6M | ||
| Q4 24 | $14.4M | $34.9M | ||
| Q3 24 | $3.9M | $33.6M | ||
| Q2 24 | $14.8M | $40.6M |
| Q1 26 | 2.4% | 66.9% | ||
| Q4 25 | 8.1% | 64.6% | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | 18.1% | 62.7% | ||
| Q1 25 | 18.3% | 67.9% | ||
| Q4 24 | 18.4% | 65.3% | ||
| Q3 24 | 17.4% | 63.2% | ||
| Q2 24 | 21.0% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -6.0% | 18.4% | ||
| Q3 25 | -7.1% | — | ||
| Q2 25 | 2.5% | -7.5% | ||
| Q1 25 | 5.2% | 12.2% | ||
| Q4 24 | 11.3% | 16.0% | ||
| Q3 24 | 5.0% | 13.8% | ||
| Q2 24 | 9.8% | 15.0% |
| Q1 26 | 0.5% | 16.4% | ||
| Q4 25 | -8.9% | 12.8% | ||
| Q3 25 | -9.1% | — | ||
| Q2 25 | -1.9% | -5.6% | ||
| Q1 25 | 0.4% | 7.1% | ||
| Q4 24 | 5.3% | 11.7% | ||
| Q3 24 | 1.3% | 11.6% | ||
| Q2 24 | 5.2% | 13.3% |
| Q1 26 | $0.01 | $0.32 | ||
| Q4 25 | $-0.19 | $0.24 | ||
| Q3 25 | $-0.19 | — | ||
| Q2 25 | $-0.04 | $-0.11 | ||
| Q1 25 | $0.01 | $0.14 | ||
| Q4 24 | $0.12 | $0.22 | ||
| Q3 24 | $0.04 | $0.21 | ||
| Q2 24 | $0.13 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.8M | $209.8M |
| Total DebtLower is stronger | $65.6M | — |
| Stockholders' EquityBook value | $1.2B | $2.1B |
| Total Assets | $2.3B | $2.6B |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $39.8M | $209.8M | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | $65.6M | — | ||
| Q4 25 | $604.2M | $260.0M | ||
| Q3 25 | $529.1M | — | ||
| Q2 25 | $533.8M | $346.0M | ||
| Q1 25 | $538.5M | $330.0M | ||
| Q4 24 | $0 | $300.0M | ||
| Q3 24 | $180.0M | $300.0M | ||
| Q2 24 | $180.0M | $319.0M |
| Q1 26 | $1.2B | $2.1B | ||
| Q4 25 | $1.2B | $2.0B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $1.0B | $2.1B | ||
| Q2 24 | $1.1B | $2.1B |
| Q1 26 | $2.3B | $2.6B | ||
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | $2.6B | ||
| Q1 25 | $2.3B | $2.6B | ||
| Q4 24 | $2.0B | $2.7B | ||
| Q3 24 | $2.0B | $2.7B | ||
| Q2 24 | $2.0B | $2.7B |
| Q1 26 | 0.06× | — | ||
| Q4 25 | 0.50× | 0.13× | ||
| Q3 25 | 0.43× | — | ||
| Q2 25 | 0.42× | 0.18× | ||
| Q1 25 | 0.41× | 0.16× | ||
| Q4 24 | 0.00× | 0.14× | ||
| Q3 24 | 0.17× | 0.14× | ||
| Q2 24 | 0.17× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AESI
| Service revenue | $139.1M | 52% |
| Product revenue | $108.9M | 41% |
| Rental revenue | $17.5M | 7% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
